Phase 3 N=61 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD
Primary: Change From Baseline in Flow Mediated Dilation at 6 Months. — -0.2; -0.4 Percent change.
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Focal Electroconvulsive Therapy for Depression
Major Depressive Disorder
Primary: Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item. — 5 Participants
Phase 3 N=92 Effects of Stress-reducing Aromatherapy
Stress-related Problems
Primary: Percent of Baseline Level of Salivary Cortisol — 170.8; 224.7; 274.7; 106.4 percentage of baseline cortisol level — p=.005
Phase 3 N=225 A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Leukemia
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 82; 84; 1; 3 Participants
Phase 3 N=169 A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) in the Naive Cohort — 98.6 Percentage of Participants
Phase 3 N=187 Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Sialorrhea
Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001
Phase 3 N=400 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
Dengue
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 — 5.3; 327.9; 6.0; 1742.5 titer
Phase 3 N=120 A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
Thromboembolism
Primary: Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis…
Phase 3 N=3,084 An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
Malaria
Primary: Incidence of Severe Malaria Meeting Case Definition 1 — 0.001; 0.002; 0.002; 0.004 events per person-year — p=0.2235
Phase 3 N=4 Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss
Spontaneous Abortion in First Trimester
Primary: Patient Enrollment — 2; 2 Participants
Phase 3 N=299 A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Time To The First Breakthrough Overt HE Episode — 13; 20; 4; 23 events — p=<0.0001
Phase 3 N=322 Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event — 78; 15; 158; 49 Participants
Phase 3 N=265 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 38.3; 25.8 percentage of participants — p=0.0324
Phase 3 N=281 Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001
Phase 3 N=89 Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) Total Score at Week 4 — -9.7; -11.6 Score on a scale — p=0.451